These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20811704)

  • 41. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
    Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
    Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. siRNA-targeted inhibition of growth hormone receptor in human colon cancer SW480 cells.
    Zhou D; Yang J; Huang WD; Wang J; Zhang Q
    World J Gastroenterol; 2013 Nov; 19(44):8108-13. PubMed ID: 24307807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.
    Chen EC; Karl TA; Kalisky T; Gupta SK; O'Brien CA; Longacre TA; van de Rijn M; Quake SR; Clarke MF; Rothenberg ME
    Gastroenterology; 2015 Sep; 149(3):705-17.e2. PubMed ID: 26026391
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.
    Lavitrano M; Ianzano L; Bonomo S; Cialdella A; Cerrito MG; Pisano F; Missaglia C; Giovannoni R; Romano G; McLean CM; Voest EE; D'Amato F; Noli B; Ferri GL; Agostini M; Pucciarelli S; Helin K; Leone BE; Canzonieri V; Grassilli E
    J Pathol; 2020 Feb; 250(2):134-147. PubMed ID: 31518438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer].
    Fan YF; Huang ZH; Nie J
    Ai Zheng; 2002 Dec; 21(12):1319-23. PubMed ID: 12520739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis.
    Zhou Y; Brattain MG
    Cancer Res; 2005 Jul; 65(13):5848-56. PubMed ID: 15994962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppressive effect of sinomenine combined with 5-fluorouracil on colon carcinoma cell growth.
    Zhang JX; Yang ZR; Wu DD; Song J; Guo XF; Wang J; Dong WG
    Asian Pac J Cancer Prev; 2014; 15(16):6737-43. PubMed ID: 25169518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Wong TW; Kramer RA; Wild R; Lee FY
    Clin Cancer Res; 2005 Aug; 11(15):5558-65. PubMed ID: 16061873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.
    Dokmanovic M; Wu Y; Shen Y; Chen J; Hirsch DS; Wu WJ
    Cancer Biol Ther; 2014 Aug; 15(8):1029-41. PubMed ID: 24835103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms.
    Ito K; Mitsunaga M; Arihiro S; Saruta M; Matsuoka M; Kobayashi H; Tajiri H
    BMC Cancer; 2016 Jan; 16():37. PubMed ID: 26810644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.